Correlation Between Kymera Therapeutics and Immunovant

Can any of the company-specific risk be diversified away by investing in both Kymera Therapeutics and Immunovant at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kymera Therapeutics and Immunovant into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Kymera Therapeutics and Immunovant, you can compare the effects of market volatilities on Kymera Therapeutics and Immunovant and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kymera Therapeutics with a short position of Immunovant. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kymera Therapeutics and Immunovant.

Diversification Opportunities for Kymera Therapeutics and Immunovant

0.29

Correlation Coefficient

Kymera Therapeutics  Immunovant

Modest diversification

The 3 months correlation between Kymera and Immunovant is 0.29. Overlapping area represents the amount of risk that can be diversified away by holding Kymera Therapeutics and Immunovant in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immunovant and Kymera Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kymera Therapeutics are associated (or correlated) with Immunovant. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immunovant has no effect on the direction of Kymera Therapeutics i.e., Kymera Therapeutics and Immunovant go up and down completely randomly.

Pair Corralation between Kymera Therapeutics and Immunovant

Given the investment horizon of 90 days Kymera Therapeutics is expected to generate 1.08 times more return on investment than Immunovant. However, Kymera Therapeutics is 1.08 times more volatile than Immunovant. It trades about 0.02 of its potential returns per unit of risk. Immunovant is currently generating about -0.03 per unit of risk. If you would invest  4,632  in Kymera Therapeutics on September 2, 2024 and sell it today you would earn a total of  53.00  from holding Kymera Therapeutics or generate 1.14% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Kymera Therapeutics  vs.  Immunovant

Kymera Therapeutics

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Kymera Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively invariable primary indicators, Kymera Therapeutics is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors.

Immunovant

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Immunovant has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Immunovant is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Kymera Therapeutics and Immunovant

The main advantage of trading using opposite Kymera Therapeutics and Immunovant positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kymera Therapeutics position performs unexpectedly, Immunovant can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunovant will offset losses from the drop in Immunovant's long position.

The idea behind Kymera Therapeutics and Immunovant pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.